These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 27295433)

  • 21. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease.
    Fenkci V; Fenkci S; Yilmazer M; Serteser M
    Fertil Steril; 2003 Jul; 80(1):123-7. PubMed ID: 12849813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High plasma level of long Pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome.
    Aydogdu A; Tasci I; Tapan S; Basaran Y; Aydogan U; Meric C; Sonmez A; Aydogdu S; Akbulut H; Taslipinar A; Uckaya G; Azal O
    Gynecol Endocrinol; 2012 Sep; 28(9):722-5. PubMed ID: 22304663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated fasting insulin is associated with cardiovascular and metabolic risk in women with polycystic ovary syndrome.
    Rasool SUA; Ashraf S; Nabi M; Rashid F; Fazili KM; Amin S
    Diabetes Metab Syndr; 2019; 13(3):2098-2105. PubMed ID: 31235143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease].
    Chen Y; Wang XJ; Jin HL; Jin L
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):751-6. PubMed ID: 23980352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
    Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
    Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome.
    Wehr E; Pilz S; Schweighofer N; Giuliani A; Kopera D; Pieber TR; Obermayer-Pietsch B
    Eur J Endocrinol; 2009 Oct; 161(4):575-82. PubMed ID: 19628650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated C-reactive protein and monocyte chemoattractant protein-1 in patients with polycystic ovary syndrome.
    Hu W; Qiao J; Yang Y; Wang L; Li R
    Eur J Obstet Gynecol Reprod Biol; 2011 Jul; 157(1):53-6. PubMed ID: 21530057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment.
    Heutling D; Schulz H; Nickel I; Kleinstein J; Kaltwasser P; Westphal S; Mittermayer F; Wolzt M; Krzyzanowska K; Randeva H; Schernthaner G; Lehnert H
    J Clin Endocrinol Metab; 2008 Jan; 93(1):82-90. PubMed ID: 17986642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between glomerular filtration rate, and metabolic and inflammatory parameters in obese and non-obese patients with polycystic ovary syndrome.
    Can M; Duran C; Guney I; Elmas H; Ayhan M; Erdem SS
    Clin Investig Arterioscler; 2020; 32(6):256-262. PubMed ID: 32773256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome.
    Javed Z; Papageorgiou M; Deshmukh H; Kilpatrick ES; Mann V; Corless L; Abouda G; Rigby AS; Atkin SL; Sathyapalan T
    Nutrients; 2019 Jan; 11(1):. PubMed ID: 30658483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation between C-reactive protein and body mass index in patients with polycystic ovarian syndrome.
    Moradi S; Mollabashi M; Kerman SR
    Gynecol Endocrinol; 2011 Jul; 27(7):480-5. PubMed ID: 20836727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Women with polycystic ovary syndrome have increased plasma chitotriosidase activity: a pathophysiological link between inflammation and impaired insulin sensitivity?
    Aydogdu A; Tasci I; Tapan S; Sonmez A; Aydogan U; Akbulut H; Uckaya G; Aydogdu S; Basaran Y; Meric C; Taslipinar A; Kurt I; Azal O
    Exp Clin Endocrinol Diabetes; 2012 May; 120(5):261-5. PubMed ID: 22549343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index.
    Samy N; Hashim M; Sayed M; Said M
    Dis Markers; 2009; 26(4):163-70. PubMed ID: 19729797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
    Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
    Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome.
    Anik Ilhan G; Yildizhan B; Pekin T
    Gynecol Endocrinol; 2019 Mar; 35(3):233-236. PubMed ID: 30303693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Raising threshold for diagnosis of polycystic ovary syndrome excludes population of patients with metabolic risk.
    Quinn MM; Kao CN; Ahmad A; Lenhart N; Shinkai K; Cedars MI; Huddleston HG
    Fertil Steril; 2016 Oct; 106(5):1244-1251. PubMed ID: 27445197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of mild hypercholesterolemia on glycemic and hormonal profiles, menstrual characteristics and the ovarian morphology of women with polycystic ovarian syndrome.
    Pergialiotis V; Trakakis E; Chrelias C; Papantoniou N; Hatziagelaki E
    Horm Mol Biol Clin Investig; 2018 Mar; 34(3):. PubMed ID: 29596052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of body mass on inflammatory markers and insulin resistance in polycystic ovary syndrome.
    Souza Dos Santos AC; Soares NP; Costa EC; de Sá JC; Azevedo GD; Lemos TM
    Gynecol Endocrinol; 2015 Mar; 31(3):225-8. PubMed ID: 25373529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.